Back to Search
Start Over
Association between time-of-day of the immune checkpoint inhibitor (ICI) infusion and disease outcomes among patients with metastatic renal cell carcinoma (mRCC)
Association between time-of-day of the immune checkpoint inhibitor (ICI) infusion and disease outcomes among patients with metastatic renal cell carcinoma (mRCC)
- Source :
- Journal of Clinical Oncology. 41:678-678
- Publication Year :
- 2023
- Publisher :
- American Society of Clinical Oncology (ASCO), 2023.
-
Abstract
- 678 Background: Recent studies have suggested an association between the time-of-day of ICI infusions and disease outcomes, including progression free survival and overall survival, among patients with cancer. (Qian et al Lancet Oncology 2021). We sought to identify whether such an association exists in patients with mRCC receiving ICIs. Methods: Patients with mRCC treated with nivolumab alone, or in combination with ipilimumab, in either first- or second-line treatment were retrospectively identified. Patients who received
- Subjects :
- Cancer Research
Oncology
Subjects
Details
- ISSN :
- 15277755 and 0732183X
- Volume :
- 41
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Oncology
- Accession number :
- edsair.doi...........9cdb62284ec655e17f13ec7ee327ee09
- Full Text :
- https://doi.org/10.1200/jco.2023.41.6_suppl.678